ReviewFrontiers in oncology2026
Redefining the concept of resectability in the landscape of perioperative treatments for lung cancer.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resectability in non-small cell lung cancer (NSCLC) is shifting from a purely anatomic and surgical concept, based on technical feasibility of an R0 resection, to an integrated, multidisciplinary determination that incorporates tumor biology, expected benefit from perioperative systemic therapy and operative risk. Contemporary guidelines emphasize that resectability-particularly in stage III disease-should be defined by an experienced multidisciplinary team (MDT) with thoracic surgical input, alongside standardized staging and biomarker assessment to guide systemic options. Perioperative immune checkpoint inhibitor (ICI) plus chemotherapy regimens have expanded the population considered for curative-intent surgery by improving pathologic response and event-free survival, while also introducing new determinants of resectability, such as likelihood of completing multimodality therapy and managing treatment-related toxicity. Resectability in locally advanced (stage III) NSCLC is a multidisciplinary determination that complete oncologic resection is achievable with acceptable operative risk, and that surgery adds value within a multimodality plan rather than being based on anatomy alone. Key elements of resectable stage III NSCLC are: R0 resection goal with guideline-concordant nodal dissection; nodal extent drives resectability more than T stage as N3 is generally unresectable while single-station, non-bulky N2 is most commonly considered potentially resectable, whereas bulky and - or multistation N2 often argues against surgery, with persistent lack of consensus in the literature. The aim of this review is to focus on the key elements currently redefining the concept of resectability in the landscape of perioperative treatment for lung cancer, with particular regard to locally advanced disease, which represents the most challenging scenario for all professionals involved in the multidisciplinary management of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.